Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 4;37(8):1499–1507. doi: 10.1097/IAE.0000000000001385

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Fig. 1. — Representative examinations of the left eye of a patient submitted to intravitreal ziv-aflibercept (Patient 7). A. Fundus picture of the left eye at baseline reveals choroidal neovascularization secondary to AMD; (B) Fundus picture of the same eye 26 weeks after intravitreal ziv-aflibercept injections; (C) FA before treatment; (D) FA 26 weeks after treatment with intravitreal ziv-aflibercept; (E–G) OCT image (scan length: 6 mm, horizontal section) at baseline, 4, and 26 weeks after treatment initiation; (H–J) 3-Dimensional response density plots at baseline, 4, and 26 weeks, showing increase in response amplitude; (K–M) Multifocal electroretinography trace array at baseline, 4, and 26 weeks.